India Oncology Market Size, Share, Trends and Forecast by Cancer Diagnostics and Treatment, Cancer Type, End Use, and Region, 2026-2034

India Oncology Market Summary:

The India oncology market size was valued at USD 11.73 Billion in 2025 and is projected to reach USD 30.01 Billion by 2034, growing at a compound annual growth rate of 10.45% from 2026-2034.  

The India oncology market is growing at a very fast pace due to the increasing incidence of cancer in the country, improving healthcare infrastructure, and the adoption of innovative technologies. Government initiatives in the healthcare sector, insurance coverage, and investments in personalized medicine are also improving the accessibility and affordability of treatments. The proliferation of specialized cancer care centres, advancements in immunotherapy and targeted therapies, and rising health awareness among the population are further propelling market expansion, strengthening the India oncology market share.

Key Takeaways and Insights:

• By Cancer Diagnostics and Treatment: Cancer treatment dominates the market with a share of 64.9% in 2025, driven by the increasing demand for advanced therapeutic interventions, expanding access to chemotherapy, immunotherapy, and targeted therapies, and growing government support for affordable cancer care across India.

• By Cancer Type: Lung cancer holds the largest share of 18.7% in 2025, reflecting the high prevalence of tobacco-related cancers, rising exposure to air pollution and environmental carcinogens, and growing diagnostic screening efforts enabling earlier detection and treatment initiation.

• By End Use: Hospitals dominate the market with a share of 53.6% in 2025, supported by the concentration of multidisciplinary oncology services, availability of advanced diagnostic and treatment infrastructure, and expanding hospital networks dedicated to comprehensive cancer care.

• By Region: West India leads the market with a share of 32.4% market share in 2025, driven by the presence of premier cancer treatment institutions, well-developed healthcare ecosystems, higher healthcare expenditure, and significant concentration of specialized oncology centres.

• Key Players: The India oncology market features a highly competitive landscape with domestic pharmaceutical manufacturers, global biopharmaceutical companies, and specialized diagnostic firms competing through product innovation, biosimilar development, strategic partnerships, and expanding oncology portfolios to capture market share.

To get more information on this market Request Sample

The India oncology market is evolving rapidly as the nation grapples with a growing cancer burden, driven by demographic shifts, lifestyle changes, and improved diagnostic capabilities. The healthcare sector is witnessing increased investments in advanced treatment modalities, including immunotherapy, precision medicine, and cell-based therapies, which are transforming patient outcomes. Government initiatives aimed at decentralizing cancer care, expanding insurance coverage, and reducing the cost of essential oncology drugs are improving accessibility for patients across socioeconomic segments. The rise of specialized cancer care facilities, the integration of artificial intelligence in cancer diagnosis, and the focus on early detection and screening programs are changing the treatment paradigm. In addition, the development of biosimilars and generic cancer medications is making treatment more accessible, and public-private partnerships are improving the cancer care infrastructure in the country, making India an emerging destination for cancer research and innovation.

India Oncology Market Trends:

Rising Adoption of Precision Medicine and Targeted Therapies

India's oncology landscape is witnessing a significant shift toward precision medicine, with growing utilization of genomic profiling and biomarker-driven treatment approaches. In February 2026, Metropolis Healthcare Limited unveiled its new Centre of Genomics and hosted a multi‑specialty genomics symposium aimed at accelerating the adoption of advanced genomic diagnostics to inform personalised cancer care pathways across India. Healthcare providers are increasingly adopting targeted therapies and antibody-drug conjugates that offer improved efficacy and reduced side effects compared to conventional treatments. This transition is expanding treatment options for patients with specific cancer mutations and supporting more personalized care pathways across the country, contributing to India oncology market growth.

Expansion of Digital Health and AI-Driven Cancer Diagnostics

Artificial intelligence and digital health technologies are increasingly being integrated into cancer diagnostics and treatment planning across India. In August 2025, diagnostics leader Dr. Lal PathLabs introduced a deep learning–based AI module to detect lymph node metastasis across multiple cancer types, helping identify spread earlier and with higher accuracy in clinical workflows. AI-powered pathology tools, imaging analysis systems, and telemedicine platforms are improving early cancer detection, enabling remote consultations, and enhancing clinical decision-making. These digital innovations are particularly valuable in bridging healthcare access gaps between urban and rural regions, supporting broader screening coverage and timely intervention.

Growth of Biosimilars and Affordable Oncology Drug Development

The expanding availability of biosimilar oncology drugs is transforming treatment accessibility in India by offering cost-effective alternatives to expensive biologic therapies. Domestic pharmaceutical companies are actively developing and launching biosimilar versions of key oncology biologics, significantly reducing treatment costs for patients. For instance, in September 2025, Alkem Laboratories launched Pertuza, a pertuzumab biosimilar for HER2‑positive breast cancer in India, developed indigenously to expand access to a critical targeted therapy at lower cost. This trend is supported by favorable regulatory pathways and growing physician confidence in biosimilar efficacy, enabling wider adoption of advanced cancer treatments across diverse patient populations.

Market Outlook 2026-2034:

The India oncology market is set for sustained growth, driven by continuous advancements in healthcare infrastructure, rising government investments in cancer care, and increasing adoption of innovative treatment modalities. Expanding insurance coverage, growing emphasis on early diagnosis, and the establishment of specialized oncology centres are expected to further accelerate market expansion. The integration of precision medicine, development of affordable biosimilar therapies, and strengthening of public health programs focused on cancer prevention and screening are creating a more supportive environment for long-term market development across the country. The market generated a revenue of USD 11.73 Billion in 2025 and is projected to reach a revenue of USD 30.01 Billion by 2034, growing at a compound annual growth rate of 10.45% from 2026-2034.

India Oncology Market Report Segmentation:

Cancer Diagnostics and Treatment Insights:

• Cancer Diagnostics
  • Tumor Biomarkers Test
  • Imaging
  • Biopsy
  • Liquid Biopsy
  • Immunohistochemistry
  • In Situ Hybridization
• Cancer Treatment
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Others

The cancer treatment dominates with a market share of 64.9% of the total India oncology market in 2025.

The cancer treatment market is currently leading the oncology market in India, due to the increasing treatment capabilities in the country, as well as the rising affordability and accessibility of cancer treatments. The increasing incidence of cancer, along with the rising affordability and accessibility of cancer treatments, is fueling investment in chemotherapy, immunotherapy, and targeted therapy infrastructure. Government initiatives that provide economic assistance for cancer treatment, as well as the development of hospital infrastructure for comprehensive cancer care, are further strengthening the leading position of the cancer treatment market.

The growing adoption of combination therapies, the introduction of novel drug formulations, and the increasing availability of affordable generic and biosimilar oncology drugs are broadening treatment reach across diverse demographics. Public health insurance schemes covering cancer care, along with expanding private healthcare investments, are ensuring that a larger proportion of the population can access essential cancer treatments. Continuous advancements in treatment protocols and supportive care practices are further enhancing patient outcomes and sustaining strong growth momentum.

Cancer Type Insights:

• Lung Cancer
• Prostate Cancer
• Colon and Rectal Cancer
• Gastric Cancer
• Esophageal Cancer
• Liver Cancer
• Breast Cancer
• Others

The lung cancer leads with a market share of 18.7% of the total India oncology market in 2025.

Lung cancer accounts for the highest market share among cancer types in India, driven by the significant prevalence of tobacco use, exposure to indoor and outdoor air pollution, and occupational hazards. The rising number of diagnosed cases, coupled with growing awareness about the importance of early screening and detection, is increasing demand for both diagnostic and treatment services. Expanded access to advanced imaging technologies and molecular testing is enabling earlier identification of lung malignancies across healthcare settings.

Advances in treatment, such as the development of targeted therapies for particular genetic mutations and immunotherapy for more advanced stages of lung cancer, are also leading to better patient outcomes and increased treatment adoption. The expanding number of tertiary cancer centers with advanced thoracic oncology programs, in addition to government-launched screening programs, is also enhancing the overall care of patients with lung cancer. Increasing physician knowledge about comprehensive treatment and palliative care is also improving the care of patients with lung cancer.

End Use Insights:

Access the comprehensive market breakdown Request Sample

• Hospitals
• Diagnostic Laboratories
• Diagnostic Imaging Centers
• Academia
• Specialty Clinics
• Others

The hospitals dominates with a share of 53.6% of the total India oncology market in 2025.

Hospitals represent the dominant end-use segment in India's oncology market, serving as the primary centres for cancer diagnosis, treatment, and long-term patient management. The concentration of multidisciplinary oncology teams, advanced surgical capabilities, radiation therapy equipment, and chemotherapy infrastructure within hospital settings drives their leading position. The expansion of both public and private hospital networks with dedicated cancer care units and specialized oncology departments is further consolidating their market share across the country.

The growing adoption of robotic-assisted surgeries, installation of advanced radiation therapy systems, and integration of comprehensive diagnostic services within hospital campuses are enhancing treatment quality and patient throughput. Government health insurance programs that primarily reimburse hospital-based cancer treatments, combined with the establishment of hub-and-spoke models connecting tertiary hospitals with district-level centres, are ensuring broader patient access. Rising investments in hospital infrastructure modernization and workforce training are further strengthening oncology service delivery capabilities.

Regional Insights:

• North India
• South India
• East India
• West India

West India exhibits a clear dominance with a 32.4% share of the total India oncology market in 2025.

West India leads the oncology market, driven by the presence of premier cancer care institutions, advanced healthcare infrastructure, and a well-established network of specialized oncology centres. The region benefits from higher healthcare expenditure, greater availability of advanced diagnostic and treatment technologies, and a significant concentration of pharmaceutical and biotechnology companies engaged in oncology research and drug development. Major metropolitan centres in the region serve as referral hubs for complex cancer cases from across the country.

The strong position in the region is further strengthened by the active government and institutional efforts in increasing cancer care capacity and the development of world-class research and treatment facilities. The rise in medical tourism for cancer care, the adoption of world-class technologies such as robotic surgery and cell-based therapies in the best hospitals, and the increase in clinical trials are improving treatment outcomes. Strong public-private partnerships and a qualified oncology workforce further add to West India's leadership position in the domestic market.

Market Dynamics:

Growth Drivers:

Why is the India Oncology Market Growing?

Rising Cancer Incidence and Growing Disease Burden

India is witnessing an increasing trend in the incidence of cancer due to demographic changes like aging and urbanization. According to recent findings from the Indian Council of Medical Research (ICMR), India recorded around 14.6 lakh new cancer cases in 2022, with one in nine people now estimated to be at lifetime risk of developing cancer, underscoring the growing burden driven by lifestyle and environmental factors. Use of tobacco, changes in food habits, a sedentary lifestyle, an increase in the incidence of obesity, and pollution are some of the factors that are contributing to the rising incidence of different types of cancers in the country. The rising incidence of cancer is thus creating a sustained demand for overall cancer care solutions. As awareness about cancer symptoms and risk factors is rising among the population, more people are seeking early treatment, thus creating a demand for cancer solutions in all categories of the healthcare system.

Expanding Government Health Programs and Policy Support

The Indian government is playing a crucial role in improving the infrastructure of cancer care through specific health programs, financial support programs, and policy changes. In February 2026, several Indian states, including Haryana, launched extensive district‑level cancer care initiatives. For example, the Haryana government inaugurated 22 day‑care cancer centres across 17 districts to provide free chemotherapy, follow‑up treatment, and supportive care locally, reducing travel burdens and out‑of‑pocket expenses for patients. National health insurance schemes are covering the cost of cancer treatment for economically vulnerable sections of society, and programs related to early detection and screening are increasing the rate of cancer diagnosis in urban and rural areas. The decentralization of cancer care through the development of cancer treatment centers at district-level hospitals is making chemotherapy and related services more accessible to patients, thus decreasing the cost of treatment. Customs duty exemptions on essential cancer drugs and controls on critical oncology drugs are making cancer treatment more affordable.

Advancements in Treatment Technologies and Drug Innovation

The emergence of innovative technologies in cancer treatment is rapidly changing the landscape of cancer treatment in India, with the launch of new immunotherapies, targeted therapies, antibody-drug conjugates, and cell therapies offering more options to doctors. For example, Indian regulators have recently cleared a range of precision oncology treatments, including immunotherapies and antibody‑drug conjugates, driving broader access to advanced targeted therapies and accelerating the shift toward personalised care. The increasing number of innovative oncology therapies in the pipeline, along with faster approval times for new indications and combinations, is offering patients more effective treatment options. The development of domestic gene therapies, the extension of biosimilar portfolios in oncology, and the adoption of latest surgical technologies such as robotic surgery are further improving treatment outcomes and adding to the growth of the oncology market.

Market Restraints:

What Challenges the India Oncology Market is Facing?

High Cost of Advanced Cancer Treatments

The expense associated with cutting-edge oncology treatments, including immunotherapies, targeted drugs, and cell-based therapies, remains a significant barrier for a large portion of India's population. Despite government subsidies and pricing interventions, out-of-pocket expenditure for cancer care continues to impose substantial financial hardship on patients and families, limiting access to the most advanced treatment options and adversely affecting treatment completion rates.

Inadequate Healthcare Infrastructure in Rural Areas

Significant disparities persist between urban and rural healthcare infrastructure for cancer care in India. Many rural and semi-urban areas lack access to essential diagnostic equipment, trained oncology specialists, and adequate treatment facilities. This compels patients to travel long distances to metropolitan centres for care, resulting in delayed diagnoses, treatment interruptions, and an increased financial burden on already vulnerable populations.

Late-Stage Cancer Diagnosis and Low Screening Rates

A considerable proportion of cancer cases in India are diagnosed at advanced stages, reducing treatment effectiveness and survival outcomes. Limited awareness about cancer symptoms, inadequate population-level screening programs, and insufficient availability of early detection tools in primary healthcare settings contribute to delayed diagnosis. Cultural barriers and stigma associated with certain cancer types further impede timely medical consultation and early intervention.

Competitive Landscape:

The India oncology market is represented by an increasingly competitive environment that is marked by the active engagement of international biopharmaceutical companies, Indian pharmaceutical companies, and dedicated diagnostic companies. Market participants are concentrating on diversifying their portfolios in the oncology segment through the launch of new drugs, the development of biosimilars, and strategic licensing agreements to enhance their product portfolios. The competition is further fueled by investments in research and development, clinical trials, and the launch of innovative treatment approaches such as immunotherapies and targeted therapies. Collaborations between international and Indian companies are helping to ensure faster market entry for innovative cancer therapies while making them more affordable. The increasing focus on personalized medicine, advances in diagnostic capabilities, and the increasing adoption of digital health solutions are also influencing competitive strategies as companies attempt to gain a larger market share.

Recent Developments:

• In January 2026, Zydus Lifesciences launched Tishtha, the world’s first biosimilar of the immuno‑oncology drug nivolumab in India to treat multiple cancers, at about one‑fourth the cost of the original, aiming to expand access and reduce treatment burden for patients.

India Oncology Market Report Coverage: